Gelesis Holdings Total Assets 2021-2022 | GLS

Gelesis Holdings total assets from 2021 to 2022. Total assets can be defined as the sum of all assets on a company's balance sheet.
Gelesis Holdings Annual Total Assets
(Millions of US $)
2021 $276
2020 $277
2019 $0
Gelesis Holdings Quarterly Total Assets
(Millions of US $)
2022-03-31 $153
2021-12-31 $146
2021-09-30 $277
2021-06-30 $277
2021-03-31 $277
2020-12-31 $0
2020-09-30 $277
2020-06-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.114B $0.011B
Gelesis is a consumer-centered biotherapeutics company advancing a novel category of treatments for weight management and gut related chronic diseases. Gelesis, formerly known as Capstar Special Purpose Acquisition Corp., is based in BOSTON.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $170.283B 10.36
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.670B 16.84
Biohaven Pharmaceutical Holding (BHVN) United States $10.157B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.957B 0.00
Arcus Biosciences (RCUS) United States $1.815B 46.02
Emergent Biosolutions (EBS) United States $1.640B 7.02
Myovant Sciences (MYOV) United Kingdom $1.243B 0.00
Zymeworks (ZYME) Canada $0.354B 0.00
Enzo Biochem (ENZ) United States $0.098B 0.00
Ambrx Biopharma (AMAM) United States $0.098B 0.00
SQZ Biotechnologies (SQZ) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00